Latest News

The latest in our partnerships, collaborations, company updates, and milestones.

March 12, 2026

Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis
March 12, 2026

Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis

Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

Read More

Inimmune Highlights Next-Generation Vaccine Adjuvants at World Vaccine Congress Europe

Read More

Inimmune to Showcase Pipeline Advances at World Vaccine Congress 2026

Read More

Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout

Read More

Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients

Read More
Medinvest Oncology Investor Conference
Inimmune to Present at the Medinvest Oncology Conference on INI-4001
Read
World Vaccine Congress
Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st
Read
Medinvest Oncology Investor Conference
Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001
Read
World Vaccine Congress (West Coast)
Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs
Read